文献速递前列腺癌

化疗后mCRPC患者恩扎卢胺治疗期间联合ADT的重要性:多中心回顾性数据

Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-09-13

该多中心回顾性研究纳入232例化疗后接受恩扎卢胺(160 mg/日)的mCRPC患者,其中29.3%同时接受ADT。中位总生存24.0个月,联合ADT与更长总生存显著相关(中位未达到 vs 18.2个月,p=0.008),校正混杂因素后风险比0.35(95%CI 0.17-0.72)。

要点

  • 化疗后mCRPC患者恩扎卢胺治疗期间联合ADT与更长总生存相关。
  • 联合ADT组中位总生存未达到,未联合组为18.2个月(p=0.008)。
  • 校正混杂因素后联合ADT仍与更长总生存相关(HR 0.35,95%CI 0.17-0.72)。

核心结论

  • 化疗后mCRPC患者在接受恩扎卢胺治疗期间联合ADT可能改善生存。

研究设计与样本

  • 回顾性多中心研究,纳入韩国9家三级中心2014至2016年间化疗后接受恩扎卢胺(160 mg/日)的232例mCRPC患者。

主要发现

  • 患者中位年龄71岁(四分位距64-75岁),Grade Group≥4者占77.6%,联合ADT率为29.3%,全因死亡率为27.1%(n=63)。
  • 中位总生存、至PSA进展时间和影像学无进展生存分别为24.0、8.0和10.0个月。
  • 联合ADT与更长总生存显著相关(中位未达到 vs 18.2个月,p=0.008)。
  • 校正混杂因素后,联合ADT仍与更长总生存相关(HR 0.35,95%CI 0.17-0.72)。

临床怎么用

  • 对于化疗后的mCRPC患者,恩扎卢胺治疗期间可考虑继续联合ADT以改善生存。

局限性

  • 回顾性研究设计可能存在选择偏倚和混杂因素,联合ADT率较低(29.3%),样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enzalutamide can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a paucity of evidence on continuing androgen-deprivation therapy (ADT) for mCRPC. Here, we analyzed the effect of concomitant ADT during enzalutamide treatment in men with mCRPC following chemotherapy. METHODS: We retrospectively reviewed the medical records of 232 patients with mCRPC who received oral enzalutamide (160 mg per day) following chemotherapy at 9 tertiary centers in Korea between 2014 and 2016. The primary endpoint was overall survival, while secondary endpoints included time to prostate-specific antigen (PSA) progression and radiographic progression-free survival. RESULTS: The median age of the patients was 71 years (interquartile range, 64-75 years). The proportion of patients in a grade group ≥4 was 77.6%. The rate of concomitant ADT was 29.3%, and the all-cause mortality rate was 27.1% (n = 63). Median overall survival, time to PSA progression, and radiographic progression-free survival were 24.0, 8.0, and 10.0 months, respectively. Notably, concomitant ADT showed a significant association with longer overall survival (median duration not reached vs. 18.2 months; p = 0.008). After adjusting for confounding factors, concomitant ADT was still associated with longer overall survival (hazard ratio, 0.35; 95% confidence interval, 0.17-0.72). CONCLUSION: Concomitant ADT during enzalutamide treatment may improve the survival of patients with mCRPC following chemotherapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Jeong CW, Kang M, Il Jung S, et al. Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. Prostate Cancer Prostatic Dis. 2018. PMID: 30214035. doi:10.1038/s41391-018-0088-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。